Roche Holding (RHHBY)
(Delayed Data from OTC)
$38.84 USD
-0.07 (-0.18%)
Updated Aug 1, 2025 03:59 PM ET
3-Hold of 5 3
C Value A Growth C Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RHHBY 38.84 -0.07(-0.18%)
Will RHHBY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RHHBY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RHHBY
CORT's Q2 Earnings Top Mark, Revenues Lag, '25 View Cut, Stock Down
ALNY Q2 Earnings Top Estimates on Higher Amvuttra Revenues, Stock Up
RHHBY: What are Zacks experts saying now?
Zacks Private Portfolio Services
AbbVie Beats on Q2 Earnings & Sales, Stock Up on Raised '25 EPS View
Biogen's Q2 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up
EXEL Q2 Earnings Top, Sales Miss on Lower Collaboration Revenues
Other News for RHHBY
Notable healthcare headlines for the week: Trump’s ultimatum to big pharma, Novo Nordisk, UnitedHealth and Moderna in focus
Market Voices: Trump vs. Big Pharma, Swiss tariffs, tariff legality
Trump Trade: Trump signs executive order raising tariff on Canada to 35%
Roche's Susvimo maintains vision over five years with two refills per year in people with ...
Genentech's Susvimo Maintains Vision Over Five Years With Two Refills Per Year in People With ...